Expert Outlook: Rhythm Pharmaceuticals Through The Eyes Of 11 Analysts
Analysts' ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 5 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $142.91, along with a high estimate of $167.00 and a low estimate of $123.00. Marking an increase of 12.53%, the current average surpasses the previous average price target of $127.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Lisa Walter | RBC Capital | Announces | Outperform | $145.00 | - |
| Derek Archila | Wells Fargo | Raises | Overweight | $145.00 | $129.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $125.00 | $123.00 |
| Joseph Stringer | Needham | Raises | Buy | $148.00 | $145.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $123.00 | $110.00 |
| Seamus Fernandez | Guggenheim | Raises | Buy | $140.00 | $120.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $141.00 | $114.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $157.00 | $141.00 |
| Jonathan Wolleben | Citizens | Raises | Market Outperform | $167.00 | $141.00 |
| Joseph Stringer | Needham | Raises | Buy | $145.00 | $120.00 |
| Samantha Semenkow | Citigroup | Announces | Buy | $136.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Rhythm Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Rhythm Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Rhythm Pharmaceuticals analyst ratings.
Discovering Rhythm Pharmaceuticals: A Closer Look
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Rhythm Pharmaceuticals: Delving into Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Rhythm Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 54.28% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -105.81% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Rhythm Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -79.29%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.34%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.